AstraZeneca and Ionis close eplontersen deal
29 December 2021 07:00 GMT AstraZeneca and Ionis close agreement to developand commercialise eplontersen AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-L\RX.\ The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America.